Bristol-Myers Squibb Co

• Leerink Partners downgraded Bristol-Myers Squibb and cut its price target. • Approaching patent cliffs for Eliquis and Opdivo threaten future revenues. • U.S. Medicare price negotiations create broader sector policy headwinds.

• ImmunityBio rallied due to strong commercial momentum for its immunotherapy ANKTIVA. • Wall Street analysts maintain a bullish consensus with an average price target of $12.75. • The company reported $113.29M in annual revenue and a net loss of $351.40M.

• United Therapeutics executed an accelerated share repurchase agreement to complete its buyback program. • The FDA accepted filings for nebulized Tyvaso and ralinepag for regulatory review. • The company reported an annual revenue of $3.18B and net profit of $1.33B.

• Wall Street downgrades drove heavy selling as valuations detached from fundamentals. • A Delaware court denied Moderna's motion to dismiss patent infringement claims. • Annual revenue reached $1.94 billion while net profit recorded a loss.

• Bristol-Myers Squibb faced profit-taking despite positive Phase 2 trial results for arlocabtagene autoleucel. • Investors reacted cautiously due to unspecified regulatory timelines and recent clinical trial enrollment pauses. • The company reports $48.19B in annual revenue and maintains solid financial operating metrics.

• Bristol-Myers Squibb shares rebounded following solid quarterly financial results and guidance. • The FDA granted accelerated approval for Zenbexus in multiple myeloma treatment. • Annual revenue reached $48.19 billion with net profit of $7.05 billion.